XNASLNSR
Market cap95mUSD
Jan 10, Last price
8.25USD
1D
-1.20%
1Q
70.81%
IPO
-32.38%
Name
LENSAR Inc
Chart & Performance
P/E
—
P/S
2.27
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.62%
Rev. gr., 5y
11.57%
Revenues
42m
+19.25%
Net income
-14m
L-26.81%
CFO
-10m
L-34.98%
Earnings
Mar 03, 2025
Profile
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 42,164 19.25% | 35,358 2.61% | ||||
Cost of revenue | 27,196 | 27,217 | ||||
Unusual Expense (Income) | ||||||
NOPBT | 14,968 | 8,141 | ||||
NOPBT Margin | 35.50% | 23.02% | ||||
Operating Taxes | (263) | |||||
Tax Rate | ||||||
NOPAT | 14,968 | 8,404 | ||||
Net income | (14,383) -26.81% | (19,651) -0.01% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 20,141 | 816 | ||||
BB yield | -52.30% | -2.71% | ||||
| Debt | ||||||
Debt current | 1,118 | 531 | ||||
Long-term debt | 4,059 | 5,075 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 9,027 | 167 | ||||
Net debt | (19,379) | (9,510) | ||||
| Cash flow | ||||||
Cash from operating activities | (9,659) | (14,856) | ||||
CAPEX | (236) | (115) | ||||
Cash from investing activities | (4,156) | (115) | ||||
Cash from financing activities | 19,762 | (1,992) | ||||
FCF | 7,854 | 5,793 | ||||
| Balance | ||||||
Cash | 24,064 | 14,674 | ||||
Long term investments | 492 | 442 | ||||
Excess cash | 22,448 | 13,348 | ||||
Stockholders' equity | (98,027) | (97,397) | ||||
Invested Capital | 157,098 | 142,351 | ||||
ROIC | 10.00% | 6.04% | ||||
ROCE | 25.34% | 18.11% | ||||
| EV | ||||||
Common stock shares outstanding | 10,971 | 10,159 | ||||
Price | 3.51 18.58% | 2.96 -50.58% | ||||
Market cap | 38,508 28.06% | 30,071 -46.45% | ||||
EV | 32,876 | 20,561 | ||||
EBITDA | 18,483 | 11,547 | ||||
EV/EBITDA | 1.78 | 1.78 | ||||
Interest | 263 | |||||
Interest/NOPBT | 3.23% | |||||